CG7870
AXP000053.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, rat probasin promoter-E1A, PSA promoter-E1B, E3 retained)
- Originator
- Calydon
- Sponsor
- Cell Genesys
Names
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (CG7870)
- Replication
- conditionally replicating
- Modifications
- rat probasin promoter drives E1A; PSA promoter/enhancer drives E1B; full E3 region retained
- Route
- intratumoral, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | Terminated | Phase 1/2 | 2004-08 | 69 | Prostate Cancer | |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | Completed | Phase 1/2 | Prostate Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 16690359 | A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in title: CG7870 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 20629483 | Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses. | Human gene therapy | 2010 | name in abstract: CG7870 |
| PMID 15832172 | Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. | Cancer gene therapy | 2005 | name in title: CG7870 |
| PMID 12435044 | Selectively replicating oncolytic adenoviruses as cancer therapeutics. | Current opinion in molecular therapeutics | 2002 | name in abstract: CG7870 |
| PMID 12522437 | Intravascular adenoviral agents in cancer patients: lessons from clinical trials. | Cancer gene therapy | 2002 | name in abstract: CG7870 |
| PMID 11212244 | Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. | Cancer research | 2001 | name in title: CV787 |
| PMID 11338935 | Technology evaluation: CV-787, Calydon Inc. | Current opinion in molecular therapeutics | 2001 | name in title: CV787 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 10485454 | The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. | Cancer research | 1999 | name in abstract: CV787 |
Notes
Formerly CV787. Intraprostatic phase I and intravenous phase I/II (NCT00103428 with docetaxel, NCT00116155) in hormone-refractory prostate cancer. Discontinued; Cell Genesys merged into BioSante in 2009.
How to cite
CG7870 (AXP000053.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000053.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.